Nuvilex (PMCB) Competitors

$0.81 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.80 -0.01 (-1.11%)

As of 05/22/2026 07:56 PM Eastern

PMCB vs. OTLK, SNTI, CRVO, SCYX, and QNTM

Should you buy Nuvilex stock or one of its competitors? MarketBeat compares Nuvilex with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuvilex include Oncobiologics (OTLK), Senti Biosciences (SNTI), CervoMed (CRVO), SCYNEXIS (SCYX), and Quantum Biopharma (QNTM). These companies are all part of the "pharmaceutical products" industry.

How does Nuvilex compare to Oncobiologics?

Oncobiologics (NASDAQ:OTLK) and Nuvilex (NASDAQ:PMCB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Oncobiologics currently has a consensus price target of $4.50, suggesting a potential upside of 1,352.08%. Given Oncobiologics' stronger consensus rating and higher probable upside, research analysts clearly believe Oncobiologics is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex has lower revenue, but higher earnings than Oncobiologics. Nuvilex is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncobiologics	$1.35M	27.74	-$62.42M	-$1.17	N/A
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A

Nuvilex's return on equity of 2.13% beat Oncobiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncobiologics	N/A	N/A	-291.28%
Nuvilex	N/A	2.13%	1.69%

Oncobiologics has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Nuvilex has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

11.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 34.2% of Nuvilex shares are owned by institutional investors. 2.8% of Oncobiologics shares are owned by insiders. Comparatively, 11.0% of Nuvilex shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Oncobiologics' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company	Overall Sentiment
Oncobiologics	Neutral
Nuvilex	Neutral

Summary

Nuvilex beats Oncobiologics on 7 of the 12 factors compared between the two stocks.

How does Nuvilex compare to Senti Biosciences?

Nuvilex (NASDAQ:PMCB) and Senti Biosciences (NASDAQ:SNTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Nuvilex's return on equity of 2.13% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Senti Biosciences	N/A	-532.05%	-103.35%

Senti Biosciences has a consensus target price of $8.75, indicating a potential upside of 786.61%. Given Senti Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Senti Biosciences is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Nuvilex has higher earnings, but lower revenue than Senti Biosciences. Nuvilex is trading at a lower price-to-earnings ratio than Senti Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Senti Biosciences	$20K	1,537.10	-$61.44M	-$1.92	N/A

In the previous week, Senti Biosciences had 8 more articles in the media than Nuvilex. MarketBeat recorded 8 mentions for Senti Biosciences and 0 mentions for Nuvilex. Nuvilex's average media sentiment score of 0.00 beat Senti Biosciences' score of -1.00 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Neutral
Senti Biosciences	Negative

Nuvilex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.09, suggesting that its share price is 109% more volatile than the broader market.

Summary

Senti Biosciences beats Nuvilex on 8 of the 15 factors compared between the two stocks.

How does Nuvilex compare to CervoMed?

Nuvilex (NASDAQ:PMCB) and CervoMed (NASDAQ:CRVO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, dividends and risk.

Nuvilex has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, CervoMed has a beta of -0.63, indicating that its share price is 163% less volatile than the broader market.

In the previous week, CervoMed had 5 more articles in the media than Nuvilex. MarketBeat recorded 5 mentions for CervoMed and 0 mentions for Nuvilex. CervoMed's average media sentiment score of 1.27 beat Nuvilex's score of 0.00 indicating that CervoMed is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvilex	Neutral
CervoMed	Positive

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 25.2% of CervoMed shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 35.4% of CervoMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CervoMed has a consensus price target of $22.60, indicating a potential upside of 638.56%. Given CervoMed's stronger consensus rating and higher probable upside, analysts plainly believe CervoMed is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CervoMed	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Nuvilex has higher earnings, but lower revenue than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
CervoMed	$4.01M	7.07	-$26.97M	-$3.28	N/A

Nuvilex has a net margin of 0.00% compared to CervoMed's net margin of -672.80%. Nuvilex's return on equity of 2.13% beat CervoMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
CervoMed	-672.80%	-136.08%	-112.62%

Summary

Nuvilex beats CervoMed on 8 of the 15 factors compared between the two stocks.

How does Nuvilex compare to SCYNEXIS?

Nuvilex (NASDAQ:PMCB) and SCYNEXIS (NASDAQ:SCYX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Nuvilex has higher earnings, but lower revenue than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
SCYNEXIS	$20.60M	1.59	-$8.61M	-$0.48	N/A

Nuvilex has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. Nuvilex's return on equity of 2.13% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
SCYNEXIS	-41.79%	-57.16%	-39.48%

Nuvilex has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

In the previous week, SCYNEXIS had 3 more articles in the media than Nuvilex. MarketBeat recorded 3 mentions for SCYNEXIS and 0 mentions for Nuvilex. Nuvilex's average media sentiment score of 0.00 beat SCYNEXIS's score of -0.44 indicating that Nuvilex is being referred to more favorably in the media.

Company	Overall Sentiment
Nuvilex	Neutral
SCYNEXIS	Neutral

SCYNEXIS has a consensus target price of $3.00, indicating a potential upside of 310.23%. Given SCYNEXIS's stronger consensus rating and higher possible upside, analysts plainly believe SCYNEXIS is more favorable than Nuvilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 4.9% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

SCYNEXIS beats Nuvilex on 8 of the 15 factors compared between the two stocks.

How does Nuvilex compare to Quantum Biopharma?

Nuvilex (NASDAQ:PMCB) and Quantum Biopharma (NASDAQ:QNTM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment.

34.2% of Nuvilex shares are owned by institutional investors. Comparatively, 1.2% of Quantum Biopharma shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 8.5% of Quantum Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Quantum Biopharma is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66M	-$1.12	N/A
Quantum Biopharma	N/A	N/A	-$26.17M	-$8.25	N/A

In the previous week, Quantum Biopharma had 1 more articles in the media than Nuvilex. MarketBeat recorded 1 mentions for Quantum Biopharma and 0 mentions for Nuvilex. Quantum Biopharma's average media sentiment score of 0.15 beat Nuvilex's score of 0.00 indicating that Quantum Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Nuvilex	Neutral
Quantum Biopharma	Neutral

Nuvilex has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Quantum Biopharma has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Quantum Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuvilex's return on equity of 2.13% beat Quantum Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
Quantum Biopharma	N/A	-941.54%	-224.41%

Summary

Nuvilex beats Quantum Biopharma on 8 of the 10 factors compared between the two stocks.

Get Nuvilex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMCB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMCB vs. The Competition

Export

Metric	Nuvilex	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.70M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.72	17.79	21.00	25.66
Price / Sales	N/A	336.21	562.18	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	0.11	5.86	10.41	7.14
Net Income	$30.66M	$74.99M	$3.57B	$335.98M
7 Day Performance	10.66%	3.11%	6.40%	4.11%
1 Month Performance	12.14%	-3.05%	3.54%	2.52%
1 Year Performance	-21.05%	34.38%	34.14%	35.04%

Nuvilex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMCB Nuvilex	0.4335 of 5 stars	$0.81 flat	N/A	-21.1%	$8.70M	N/A	N/A	4	Positive News High Trading Volume
OTLK Oncobiologics	1.8167 of 5 stars	$0.33 +22.0%	$4.50 +1,251.4%	-80.6%	$33M	$1.35M	N/A	20	Gap Up High Trading Volume
SNTI Senti Biosciences	2.2705 of 5 stars	$0.98 +0.4%	$8.75 +789.1%	-69.2%	$30.52M	$20K	N/A	4	Negative News
CRVO CervoMed	3.7098 of 5 stars	$3.09 -4.6%	$22.60 +631.4%	-63.9%	$30M	$4.01M	N/A	4	Positive News Gap Down
SCYX SCYNEXIS	1.8994 of 5 stars	$0.71 +6.3%	$3.00 +322.5%	-5.8%	$29.83M	$20.60M	N/A	60	Stock Split Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMCB) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuvilex (PMCB) Competitors

PMCB vs. OTLK, SNTI, CRVO, SCYX, and QNTM

How does Nuvilex compare to Oncobiologics?

Summary

How does Nuvilex compare to Senti Biosciences?

Summary

How does Nuvilex compare to CervoMed?

Summary

How does Nuvilex compare to SCYNEXIS?

Summary

How does Nuvilex compare to Quantum Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuvilex (PMCB) Competitors

PMCB vs. OTLK, SNTI, CRVO, SCYX, and QNTM

How does Nuvilex compare to Oncobiologics?

Do analysts rate OTLK or PMCB?

Which has higher earnings & valuation, OTLK or PMCB?

Is OTLK or PMCB more profitable?

Which has more risk & volatility, OTLK or PMCB?

Do insiders & institutionals hold more shares of OTLK or PMCB?

Does the media refer more to OTLK or PMCB?

Summary

How does Nuvilex compare to Senti Biosciences?

Do institutionals and insiders believe in PMCB or SNTI?

Is PMCB or SNTI more profitable?

Do analysts rate PMCB or SNTI?

Which has better earnings and valuation, PMCB or SNTI?

Does the media favor PMCB or SNTI?

Which has more volatility & risk, PMCB or SNTI?

Summary

How does Nuvilex compare to CervoMed?

Which has more volatility & risk, PMCB or CRVO?

Does the media refer more to PMCB or CRVO?

Do institutionals & insiders believe in PMCB or CRVO?

Do analysts recommend PMCB or CRVO?

Which has preferable valuation & earnings, PMCB or CRVO?

Is PMCB or CRVO more profitable?

Summary

How does Nuvilex compare to SCYNEXIS?

Which has higher valuation and earnings, PMCB or SCYX?

Is PMCB or SCYX more profitable?

Which has more risk and volatility, PMCB or SCYX?

Does the media favor PMCB or SCYX?

Do analysts prefer PMCB or SCYX?

Do insiders & institutionals have more ownership in PMCB or SCYX?

Summary

How does Nuvilex compare to Quantum Biopharma?

Do insiders and institutionals believe in PMCB or QNTM?

Which has stronger valuation & earnings, PMCB or QNTM?

Does the media refer more to PMCB or QNTM?

Which has more volatility & risk, PMCB or QNTM?

Do analysts rate PMCB or QNTM?

Is PMCB or QNTM more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB vs. The Competition

Nuvilex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools